Platelet-targeted gene therapy is an emerging therapeutic strategy aimed at using genetic engineering techniques to modulate the function and activity of platelets, enabling sustained expression of new proteins in vivo to treat specific diseases.521–523 Hemophilia A (HA) is an X-linked genetic disorder caused by a deficiency of FVIII. The gene discussed is F8; the disease is hemophilia A.